89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
A phase 3 trial of Zirconium-89 girentuximab run by Telix Pharmaceuticals (Innovations) Pty Limited in renal cell carcinoma, now recruiting.
Overview
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study is a phase 3 interventional study registered as NCT06750419 by Telix Pharmaceuticals (Innovations) Pty Limited, with 82 participants planned, started 2024-11-06. Conditions listed: Clear Cell Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialZIRCON
Shares Zirconium-89 girentuximab, Telix Pharmaceuticals, Zirconium-89, Renal cell carcinoma.
- Key paperZIRCON: [89Zr]Zr-girentuximab PET-CT for detecting clear-cell renal cell carcinoma
Shares Zirconium-89 girentuximab, Telix Pharmaceuticals, Zirconium-89, Renal cell carcinoma.
- OpportunityCAIX imaging of the indeterminate renal mass
Shares Zirconium-89 girentuximab, CAIX (carbonic anhydrase IX), Zirconium-89, Renal cell carcinoma.
- IdeaCAIX theranostics: 89Zr-girentuximab PET and 177Lu/225Ac-girentuximab therapy
Shares CAIX (carbonic anhydrase IX), Telix Pharmaceuticals, Zirconium-89, Renal cell carcinoma.
- TrialPhase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
- PathwayVHL / HIF oxygen sensing
Shares CAIX (carbonic anhydrase IX), Zirconium-89, Renal cell carcinoma.
- TechnologyCAIX PET (89Zr-girentuximab)
Shares CAIX (carbonic anhydrase IX), Telix Pharmaceuticals, Zirconium-89, Renal cell carcinoma.
- TechnologyImmuno-PET
Shares Zirconium-89 girentuximab, Zirconium-89.